Relationship between the Ratio of Triglyceride to High Density Lipoprotein and Glycated Hemoglobin A in 4-5 Years Follow-up in Non-Diabetic Adults

2018 ◽  
Vol 8 (3) ◽  
pp. 462-467
Author(s):  
Hyun-Ha Kim ◽  
Woo-Joo Park ◽  
Soo-Eun Jang ◽  
Seung-Ryong Yoo ◽  
Hyeona-A Lee ◽  
...  
Keyword(s):  
High Density Lipoprotein ◽  
Glycated Hemoglobin ◽  
Density Lipoprotein ◽  
High Density ◽  
Hemoglobin A ◽  
Glycated Hemoglobin A

scholarly journals Independent and Joint Associations of Sedentary Behavior and Physical Activity with Cardiometabolic Health Markers in the 1970 British Birth Cohort

2019 ◽  
Author(s):  
Bo-Huei Huang ◽  
Mark Hamer ◽  
Sebastien Chastin ◽  
Annemarie Koster ◽  
Natalie Pearson ◽  
...  
Keyword(s):  
Physical Activity ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Sedentary Time ◽  
Glycated Hemoglobin ◽  
Vigorous Physical Activity ◽  
Density Lipoprotein ◽  
High Density ◽  
Breaks In Sedentary Time ◽  
Joint Associations

AbstractObjectiveTo examine the independent and joint associations thigh-worn accelerometry assessed sedentary time and moderate to vigorous physical activity with cardiometabolic health markers.DesignCross-sectional study embedded in the age-46 wave an established birth cohort, the 1970 British Birth Cohort.SettingPopulation-based sample from Great Britain (England, Scotland, and Wales).MethodsOutcome measures included: body mass index, waist-to-hip ratio, blood pressure, glycated hemoglobin, high-density lipoprotein cholesterol, total cholesterol, triglycerides, and c-reactive protein. Sedentary behavior and other physical activity exposures, recorded by a thigh-worn activPAL3 accelerometry, included: daily sedentary time, breaks in sedentary time, daily time spent in moderate-to-vigorous physical activity. Multiple linear regression analyses, multiple logistic regression analyses, and general linear models were conducted as applicable.Results4,634 participants were available for the final analysis. After adjusting for potential confounders and moderate-to-vigorous physical activity, daily sedentary time was positively associated with triglycerides (β=0.052 [0.015, 0.089]) and inversely associated with high-density lipoprotein cholesterol (β=-0.015 [-0.022, -0.010]). Daily prolonged sedentary time (≥ 60 minutes) was positively associated with both glycated hemoglobin and log-transformed c-reactive protein (β=0.240 [0.030, 0.440] and 0.026 [0.007, 0.045], respectively) and inversely associated with systolic blood pressure and high-density lipoprotein cholesterol (β=-0.450 [-0.760, -0.150] and -0.013 [-0.022, -0.003], respectively). After adjusting for potential confounders and daily sedentary time, daily breaks in sedentary time were inversely associated with glycated hemoglobin (β=-0.020 [-0.037, -0.003]), and positively associated with both triglycerides and systolic blood pressure (β=0.006 [0.002, 0.010] and 0.030 [0.002, 0.050], respectively). The joint associations of prolonged sedentary time and moderate-to-vigorous physical activity with the prevalence of diabetes were not statistically significant.ConclusionProlonged sedentary time (≥ 60 minutes) and daily breaks in sedentary time were deleteriously associated with glycated hemoglobin, although we found no evidence that there were joint moderate-to-vigorous physical activity and sitting associations.

Abstract P175: High-density Lipoprotein Cholesterol and Mortality Prior to Age 90 in a Cohort of Male Physicians

Circulation ◽  
2012 ◽  
Vol 125 (suppl_10) ◽  
Author(s):  
Catherine Rahilly-Tierney ◽  
Howard D Sesso ◽  
J. Michael Gaziano ◽  
Luc Djousse
Keyword(s):  
High Density Lipoprotein ◽  
Lower Risk ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cox Proportional Hazards ◽  
High Density ◽  
Health Study ◽  
Inverse Association ◽  
Cvd Mortality

BACKGROUND: Few studies have examined prospectively the relationship between baseline high-density lipoprotein (HDL) cholesterol and longevity. OBJECTIVES: We sought to examine whether higher HDL levels were associated with lower risk of all-cause, cardiovascular (CVD), and non-CVD mortality prior to age 90 in the Physicians’ Health Study (PHS). METHODS: We considered a baseline cohort of 1351 PHS participants who provided bloods between 1997 and 2001 and were old enough to reach age 90 by March 4, 2009. Included subjects had complete baseline data on HDL and total cholesterol; lifestyle factors including smoking, exercise, alcohol consumption, and BMI; and comorbidities including hypertension, diabetes mellitus, congestive heart failure, cancer, and stroke. We used Cox proportional hazards to determine the HRs and 95% CIs for all-cause, CVD, and non-CVD mortality prior to age 90, adjusting for baseline age, co-morbidities, and non-HDL cholesterol. RESULTS: At baseline, the cohort had a mean (SD) age of 81.9 (2.9) years and a mean (SD) HDL cholesterol of 44.8(16.5) mg/dL. After a mean follow-up of 6.8 years (maximum 12.3 years), 501 (37.1%) of men died prior to age 90. In multi-variable adjusted analyses, men in the highest HDL-C quartile (≥54.1 mg/dL) had a 28% lower risk (HR 0.72, 95% CI 0.55-0.95) of all-cause mortality prior to age 90 compared to men in the lowest HDL-C quartile (<32.8 mg/dL). From the lowest to highest HDL quartile, age-adjusted HR(95%CI) for CVD mortality prior to age 90 were 0.66 (0.44-0.99), 0.58 (0.38-0.90), and 0.53 (0.34-0.82) (p for trend 0.004). There was no significant association between baseline HDL cholesterol and non-CVD death. CONCLUSION: In a cohort of older male physicians with long-term follow-up, baseline HDL cholesterol was inversely associated with the risk of dying prior to age 90, largely explained by an inverse association between HDL and CVD mortality.

scholarly journals The preablation monocyte/ high density lipoprotein ratio predicts the late recurrence of paroxysmal atrial fibrillation after radiofrequency ablation

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
She-an Chen ◽  
Man-man Zhang ◽  
Meifang Zheng ◽  
Fei Liu ◽  
Lei Sun ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Radiofrequency Ablation ◽  
High Density Lipoprotein ◽  
Predictive Value ◽  
Density Lipoprotein ◽  
Late Recurrence ◽  
High Density ◽  
Significant Difference ◽  
Af Recurrence

Abstract Background The monocyte/high-density lipoprotein ratio (MHR) has emerged as a promising alternative biomarker in the fields of cardiovascular disease and atrial fibrillation (AF). This retrospective study was aimed to explore the predictive value of the MHR for the late recurrence of AF after radiofrequency ablation. Methods From April 2015 to October 2018, patients with paroxysmal AF who had undergone radiofrequency catheter ablation at Subei People’s Hospital of Jiangsu Province were enrolled in our study. All the participants were observed until November 2019 after the procedure. During the postoperative follow up, the patients were categorized into the recurrence group and maintenance of sinus rhythm group based on who had experienced AF recurrence. Results One hundred twenty-five patients were diagnosed with paroxysmal AF, with an average age of 61.2 ± 9.3 years. Forty-seven patients had developed late recurrence during a mean follow up of 25.1 ± 12.0 months. The AF recurrence event rates were significantly increased in the highest MHR tertile compared with those in the lowest MHR tertile (22.0% vs. 57.1%; P < 0.05). On multivariate logistic regression analysis, the preablation MHR (OR = 1.34; 95% CI = 1.12 ~ 1.60; P = 0.001) and left atrial diameter (LAD) (OR = 1.21, 95% CI = 1.08 ~ 1.35; P = 0.001) were independent risk factors predicting the recurrence of AF after radiofrequency ablation. Furthermore, receiver operating characteristic (ROC) curve analysis revealed that the area under the curve (AUC) of the MHR was 0.712 (95% CI = 0.618 ~ 0.806; P = 0.000) and that of LAD was 0.739 (95% CI = 0.653 ~ 0.814; P = 0.000). Z-test found no significant difference between the MHR and LAD regarding the AUC (Z = 0.451; P = 0.652). Conclusion An elevated preablation MHR was associated with an increased risk of the postoperative recurrence of AF. Additionally, the MHR independently predicted the late recurrence of paroxysmal AF after radiofrequency ablation, with the same predictive value as LAD.

scholarly journals Role of High-Density Lipoprotein Cholesterol (HDL-C) as a Clinical Predictor of Decompensation in Patients with Chronic Liver Disease (CLD)

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Harshavardhan Rao B ◽  
Priya Nair ◽  
Anoop K. Koshy ◽  
S. Krishnapriya ◽  
C. R. Greeshma ◽  
...  
Keyword(s):  
Liver Disease ◽  
High Density Lipoprotein ◽  
Chronic Liver Disease ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Chronic Liver ◽  
Lipoprotein Cholesterol

Introduction. Systemic inflammation triggered by bacterial products like lipopolysaccharides (LPS) in the circulation is an important factor leading to decompensation in patients with chronic liver disease (CLD). High-density lipoprotein cholesterol (HDL-C) has a significant role in innate immune response to LPS in the circulation and could therefore increase the risk for decompensation in patients with CLD. In this study, we have explored the role of HDL-C as a prognostic marker for decompensation. Methods. This was a prospective, observational, cohort study where consecutive patients with CLD were included. Patients with cholestatic liver disease and hepatocellular carcinoma were excluded. Fasting lipids were measured in all patients at the time of recruitment. Each patient was carefully followed up for development of decompensation events such as new-onset/worsening ascites, hepatic encephalopathy, or variceal bleed during follow-up. Results. A total of 170 patients were included (mean age 60 ± 11.5 years, M : F = 6 : 1 ). At the end of follow-up, 97/170 patients (57%) had decompensation events. Mean HDL-C levels were significantly lower among patients with decompensation ( 27.5 ± 15  mg/dL vs. 43.5 ± 13.9  mg/dL; p value 0.004). Using ROC analysis, cut-off for HDL-C of 36.4 mg/dL was identified. On multivariate analysis, HDL-C ( OR = 6.072 ; 95% CI 2.39-15.39) was found to have an independent association with risk of decompensation. Conclusions. HDL-C level (<36.4 mg/dL) is a reliable marker for risk of decompensation and can be a useful addition to existing prognostic scoring systems in CLD. It can be a valuable tool to streamline treatment protocols and prioritise liver transplantation.

scholarly journals Daily Consumption of Virgin Coconut Oil Increases High-Density Lipoprotein Cholesterol Levels in Healthy Volunteers: A Randomized Crossover Trial

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Surarong Chinwong ◽  
Dujrudee Chinwong ◽  
Ampica Mangklabruks
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Crossover Trial ◽  
Density Lipoprotein ◽  
Coconut Oil ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Plasma Lipoproteins ◽  
Daily Consumption

This open-label, randomized, controlled, crossover trial assessed the effect of daily virgin coconut oil (VCO) consumption on plasma lipoproteins levels and adverse events. The study population was 35 healthy Thai volunteers, aged 18–25. At entry, participants were randomly allocated to receive either (i) 15 mL VCO or (ii) 15 mL 2% carboxymethylcellulose (CMC) solution (as control), twice daily, for 8 weeks. After 8 weeks, participants had an 8-week washout period and then crossed over to take the alternative regimen for 8 weeks. Plasma lipoproteins levels were measured in participants at baseline, week-8, week-16, and week-24 follow-up visits.Results. Of 32 volunteers with complete follow-up (16 males and 16 females), daily VCO intake significantly increased high-density lipoprotein cholesterol by 5.72 mg/dL (p=0.001) compared to the control regimen. However, there was no difference in the change in total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels between the two regimens. Mild diarrhea was reported by some volunteers when taking VCO, but no serious adverse events were reported.Conclusion. Daily consumption of 30 mL VCO in young healthy adults significantly increased high-density lipoprotein cholesterol. No major safety issues of taking VCO daily for 8 weeks were reported.

Sign in / Sign up

Export Citation Format

Share Document